This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Blake, G. J. Articles by Ridker, P. M. Search for Related Content PubMed PubMed Citation Articles by Blake, G. J. Articles by Ridker, P. M.

A prospective evaluation of lipoprotein-associated phospholipase A₂ levels and the risk of future cardiovascular events in women

Gavin J. Blake, MB, MSc, MRCPI^* , Nisha Dada, BS^||, Jonathan C. Fox, MD, FACC^¶, JoAnn E. Manson, MD, DrPH and Paul M. Ridker, MD, MPH, FACC^*,*

^* Center for Cardiovascular Disease Prevention, Boston, Massachusetts, USA
Division of Preventive Medicine, Boston, Massachusetts, USA
Division of Cardiovascular Disease, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA
Leducq Center for Cardiovascular Research, Harvard Medical School, Boston, Massachusetts, USA
^|| diaDexus, Inc., Santa Clara, California, USA
^¶ GlaxoSmithKlein, Philadelphia, Pennsylvania, USA

View larger version (20K): [in a new window]   Figure 1 Adjusted relative risks of cardiovascular events according to increasing quartiles of lipoprotein-associated phospholipase A2 (Lp-PLA2) and C-reactive protein (CRP) compared to the lowest quartile. The error bars indicate the 95% CIs. The p values are for the highest quartile of plasma marker compared to the lowest quartile. These models were adjusted for random assignment to aspirin and vitamin E and for the following risk factors: low-density lipoprotein and high-density lipoprotein cholesterol, body mass index, a history of hypertension, a history of diabetes, a parental history of myocardial infarction, frequency of exercise and current use of hormone replacement therapy.